Articles

A-104 THE INTERACTION OF FACTOR V AND TISSUE FACTOR PATHWAY INHIBITOR IN A MYELOMA PATIENT WITH ACQUIRED FACTOR V DEFICIENCY

BJH - volume 9, issue Abstract Book BSTH, february 2018

E. De Maertelaere , E. Castoldi , I. Van Haute , D. Deeren , K. Devreese

Read more

O.5 Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): an interim analysis from the Belgian Hematology Society (BHS)

BJH - volume 8, issue Abstract Book BHS, february 2017

X. Poiré MD, C. Graux MD, PhD, A. Ory , J. Jamart , F. Frédéric , H. Schoemans MD, PhD, P. Lewalle MD, PhD, A. De Becker MD, D. Deeren , Z. Berneman MD, PhD, T. Kerre MD, PhD, P. Zachée MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD

Read more

P58 Extremely elevated C – reactive protein: a bad omen for haematological patients?

BJH - volume 8, issue Abstract Book BHS, february 2017

L. Tryssesoone , D. Deeren

Read more

P2.02 Belgian consensus on the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria

BJH - volume 7, issue Abstract Book BHS, january 2016

B. Devalet , N. Boeckx MD, PhD, B. Chatelain PharmD, C. Chatelain MD, D. Deeren , A. Gothot MD, PhD, S. Meers MD, PhD, T. Devos MD, PhD

Read more

P3.01 Hematopoietic progenitor cell count in mobilized peripheral blood by Sysmex XE-2100: added value in clinical practice?

BJH - volume 6, issue Abstract Book BHS, january 2015

S. Desmet , T. Maenhout , E. Moreau , I. Van Haute , D. Deeren

Read more

P3.05 Efficacy of azacitidine in Belgian patients: results of a real-life non-interventional, post-marketing survey

BJH - volume 5, issue Abstract Book BHS, january 2014

S. Meers MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD, C. Graux MD, PhD, G. Bries MD, PhD, D. Deeren , I. Vrelust MD, P. Pierre , C. Ravoet , K. Theunissen , F. Trullemans , L. Noens MD, PhD, P. Mineur MD

Read more